Suppr超能文献

复发性胶质母细胞瘤再程放疗后的预后参数及结果

Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.

作者信息

Zwirner K, Paulsen F, Schittenhelm J, Borchers C, Skardelly M, Zips D, Eckert F

机构信息

Department of Radiation Oncology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.

Neuro-Oncology Center, Comprehensive Cancer Center Tuebingen, Tuebingen, Germany.

出版信息

Acta Neurol Scand. 2017 Sep;136(3):239-245. doi: 10.1111/ane.12719. Epub 2016 Dec 26.

Abstract

OBJECTIVES

In progressive glioblastoma, salvage treatment remains unstandardized, response is highly variable, and detailed analysis of individual approaches is mandatory. Re-irradiation is an established option in the therapy of progressive glioblastoma. Thus, we analysed outcome and prognostic parameters of patients with re-irradiated glioblastoma treated at our institution since 1998.

MATERIALS AND METHODS

In a total of 51 patients, clinical and treatment parameters were collected and analysed retrospectively. Re-irradiation protocols included radiosurgery, hypofractionated radiotherapy or normofractionated radiotherapy. Outcome was analysed regarding prognostic factors in this highly selected cohort.

RESULTS

Median overall survival after primary diagnosis was 28.8 months. Patients re-irradiated with single-dose stereotactic radiosurgery or hypofractionated regimes showed a superior overall survival after primary diagnosis compared to normofractionated treatment. Positive prognostic factors included a smaller gross tumour volume and younger age. A methylated MGMT promoter approached statistical significance as a positive factor regarding overall survival after re-irradiation. Further well-known prognostic factors as extension of the initial resection and the concomitance of temozolomide with the initial radiation treatment only appeared relevant in a subgroup of four long-term survivors.

CONCLUSIONS

The favourable results regarding overall survival are probably due to patient selection for re-irradiation. If technically feasible, stereotactic radiosurgery or hypofractionated regimes should be preferred. In this highly selected re-irradiation cohort, only some of the well-known prognostic factors of the primary tumour setting were found to influence overall survival significantly. In contrast, also some patients presenting with unfavourable predictive parameters showed an encouraging course of disease and thus should not be excluded from re-irradiation.

摘要

目的

在进展性胶质母细胞瘤中,挽救性治疗仍未标准化,反应高度可变,因此必须对个体治疗方法进行详细分析。再程放疗是进展性胶质母细胞瘤治疗中的一种既定选择。因此,我们分析了自1998年以来在我院接受再程放疗的胶质母细胞瘤患者的治疗结果和预后参数。

材料与方法

共收集51例患者的临床和治疗参数并进行回顾性分析。再程放疗方案包括立体定向放射外科、低分割放疗或常规分割放疗。分析了这一高度选择队列中的预后因素。

结果

初次诊断后的中位总生存期为28.8个月。与常规分割治疗相比,接受单剂量立体定向放射外科或低分割放疗方案再程放疗的患者在初次诊断后的总生存期更长。阳性预后因素包括肿瘤总体积较小和年龄较轻。甲基化的MGMT启动子作为再程放疗后总生存期的阳性因素接近统计学意义。其他众所周知的预后因素,如初次切除范围和替莫唑胺与初次放疗同时使用,仅在4例长期存活者的亚组中显示出相关性。

结论

总生存期的良好结果可能归因于再程放疗的患者选择。如果技术可行,应优先选择立体定向放射外科或低分割放疗方案。在这个高度选择的再程放疗队列中,仅发现一些原发性肿瘤的众所周知的预后因素对总生存期有显著影响。相比之下,一些具有不利预测参数的患者也显示出令人鼓舞的病程,因此不应被排除在再程放疗之外。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验